ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chron...
January 13 2020 - 8:00AM
ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of direct lytic
agents (DLAs), including lysins and amurin peptides, as new medical
modalities for the treatment of life-threatening,
antibiotic-resistant infections, today announced that it has
extended early access to exebacase to individual named patients
with chronic post-operative prosthetic joint infections (PJIs)
under Temporary Authorizations for Use (ATUs) from the French
National Agency for Medicines and Health Products Safety (ANSM) in
collaboration with Dr. Tristan Ferry at the Hôpital de la Croix
Rousse in Lyon, France.
Four patients with longstanding,
treatment-refractory PJIs have been treated with direct
administration (i.e. intra-articular) of exebacase to the affected
joint under ATUs. Based on promising clinical signals in these
exebacase-treated patients, temporary authorization for use of
exebacase has now been extended to patients with Staphylococcal PJI
occurring early in the postoperative period, to potentially avoid
significant loss of function.
“Staphylococcal PJIs pose significant treatment
challenges due to biofilm formation which renders conventional
antibiotics ineffective and necessitates surgical removal and
replacement of the joint. Exebacase has the demonstrated potent
ability to eradicate Staphylococcal biofilms in vitro and in animal
models, and thus may have potential as a therapeutic agent
administered directly to the joint to clear the infection and
possibly reduce the need for surgical intervention,” said Cara
Cassino, MD, Chief Medical Officer and Executive Vice President of
Research and Development of ContraFect. “This would be a
significant benefit to patients world-wide, as there are currently
no approved medical treatments for PJIs, and surgical
reimplantation of a new prosthetic joint can be associated with
substantial disability and loss of function.”
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing differentiated biologic therapies for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our platform of DLAs, which
include lysins and amurin peptides. Lysins are a new class of DLAs
which are recombinantly produced antimicrobial proteins with a
novel mechanism of action associated with the rapid killing of
target bacteria, eradication of biofilms and synergy with
conventional antibiotics. Amurin peptides are a new class of DLAs,
which exhibit broad-spectrum activity against a wide range of
antibiotic-resistant Gram-negative pathogens, including Pseudomonas
aeruginosa (P. aeruginosa), Acinetobacter baumannii, and
Enterobacter species. We believe that the properties of our lysins
and amurin peptides will make them suitable for targeting
antibiotic-resistant organisms, such as methicillin-resistant Staph
aureus (MRSA) and P. aeruginosa, which can cause serious infections
such as bacteremia, pneumonia and osteomyelitis. We have completed
a Phase 2 clinical trial for the treatment of Staph aureus
bacteremia, including endocarditis, with our lead lysin candidate,
exebacase, which is the first lysin to enter clinical studies in
the U.S.
Follow ContraFect on Twitter @ContraFectCorp and
LinkedIn.
Forward-Looking
Statements:
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities laws.
Forward-looking statements can be identified by words such as
“projects,” “may,” “will,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential,” “promise” or similar references to future periods.
Examples of forward-looking statements in this release include,
without limitation, statements regarding ContraFect’s ability to
discover and develop DLAs as new medical modalities for the
treatment of life-threatening, antibiotic-resistant infections,
statements made regarding compassionate use, ATUs, PJIs, treated
patients, treatment results and anticipated treatments, comments
made by ContraFect’s chief medical officer, ContraFect’s ability to
address life threatening infections using its DLA platform, whether
lysins are a new class of DLAs which are recombinantly produced,
antimicrobial proteins with a novel mechanism of action associated
with the rapid killing of target bacteria, eradication of biofilms
and synergy with conventional antibiotics, whether amurins exhibit
broad-spectrum activity against a wide range of
antibiotic-resistant Gram-negative pathogens and whether the
properties of ContraFect’s lysins and amurins will make them
suitable for targeting antibiotic-resistant organisms, such as
methicillin-resistant Staph aureus and P. aeruginosa.
Forward-looking statements are statements that are not historical
facts, nor assurances of future performance. Instead, they are
based on ContraFect’s current beliefs, expectations and assumptions
regarding the future of its business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are beyond ContraFect’s control, including those detailed
under the caption “Risk Factors” in ContraFect's filings with the
Securities and Exchange Commission. Actual results may differ from
those set forth in the forward-looking statements. Important
factors that could cause actual results to differ include, among
others, our ability to develop treatments for drug-resistant
infectious diseases. Any forward-looking statement made by
ContraFect in this press release is based only on information
currently available and speaks only as of the date on which it is
made. Except as required by applicable law, ContraFect expressly
disclaims any obligations to publicly update any forward-looking
statements, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor Relations
Contacts:
Michael MessingerContraFect CorporationTel:
914-207-2300Email: mmessinger@contrafect.com
Lauren StivalStern Investor RelationsTel:
212-362-1200Email: lauren.stival@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Sep 2023 to Sep 2024